A continuous delivery system of IL‐1 receptor antagonist reduces angiogenesis and inhibits tumor development
Open Access
- 3 November 2003
- journal article
- fj express-summarie
- Published by Wiley in The FASEB Journal
- Vol. 18 (1) , 161-163
- https://doi.org/10.1096/fj.03-0483fje
Abstract
The involvement of interleukin-1 (IL-1) in inflammation, tumor growth, and metastasis makes it an attractive target for therapeutic intervention. Here, we show that a continuous delivery of a low, bu...Keywords
Funding Information
- Association for International Cancer Research
This publication has 18 references indexed in Scilit:
- Interleukin-1—a major pleiotropic cytokine in tumor–host interactionsPublished by Elsevier ,2002
- Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonistArthritis & Rheumatism, 1998
- Characterization of microencapsulated liposome systems for the controlled delivery of liposome-associated macromoleculesJournal of Controlled Release, 1997
- Blood Vessel Formation: What Is Its Molecular Basis?Cell, 1996
- Fusion of a Signal Sequence to the Interleukin-1β Gene Directs the Protein from Cytoplasmic Accumulation to Extracellular ReleaseCellular Immunology, 1996
- Interleukin 1 (IL-1)-Dependent Melanoma Hepatic Metastasis In Vivo; Increased Endothelial Adherence by IL-1-Induced Mannose Receptors and Growth Factor Production In VitroJNCI Journal of the National Cancer Institute, 1996
- Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humansCytokine, 1992
- Tumor Angiogenesis and Metastasis — Correlation in Invasive Breast CarcinomaNew England Journal of Medicine, 1991
- Colorimetric assay fop cellular activity in microcapsulesBiomaterials, 1990
- Microencapsulated Islets as Bioartificial Endocrine PancreasScience, 1980